Institute of Biochemistry and Molecular Medicine and Swiss National Centre of Competence in Research (NCCR) TransCure, University of Bern, CH-3012, Bern, Switzerland.
Division of Experimental and Clinical Research, Vetsuisse Faculty, University of Bern, CH-3001, Bern, Switzerland.
Virus Res. 2019 Jan 2;259:28-37. doi: 10.1016/j.virusres.2018.10.003. Epub 2018 Oct 5.
Morbilliviruses (e.g. measles virus [MeV] or canine distemper virus [CDV]) employ the attachment (H) and fusion (F) envelope glycoproteins for cell entry. H protein engagement to a cognate receptor eventually leads to F-triggering. Upon activation, F proteins transit from a prefusion to a postfusion conformation; a refolding process that is associated with membrane merging. Small-molecule morbilliviral fusion inhibitors such as the compound 3G (a chemical analog in the AS-48 class) were previously generated and mechanistic studies revealed a stabilizing effect on morbilliviral prefusion F trimers. Here, we aimed at designing 3G-resistant CDV F mutants by introducing single cysteine residues at hydrophobic core positions of the helical stalk region. Covalently-linked F dimers were generated, which highlighted substantial conformational flexibility within the stalk to achieve those irregular F conformations. Our findings demonstrate that "top-stalk" CDV F cysteine mutants (F-V571C and F-L575C) remained functional and gained resistance to 3G. Conversely, although not all "bottom-stalk" F cysteine variants preserved proper bioactivity, those that remained functional exhibited 3G-sensitivity. According to the recently determined prefusion MeV F trimer/AS-48 co-crystal structure, CDV residues F-V571 and F-L575 may directly interact with 3G. A combination of conformation-specific anti-F antibodies and low-resolution electron microscopy structural analyses confirmed that 3G lost its stabilizing effect on "top-stalk" F cysteine mutants thus suggesting a primary resistance mechanism. Overall, our data suggest that the fusion inhibitor 3G stabilizes prefusion CDV F trimers by docking at the top of the stalk domain.
副黏病毒(例如麻疹病毒[MeV]或犬瘟热病毒[CDV])利用附着(H)和融合(F)包膜糖蛋白进入细胞。H 蛋白与同源受体的结合最终导致 F 的触发。激活后,F 蛋白从预融合状态转变为融合后状态;这是一个与膜融合相关的重折叠过程。小分子副黏病毒融合抑制剂,如化合物 3G(AS-48 类的化学类似物),以前曾被开发出来,并且机制研究表明它对副黏病毒预融合 F 三聚体具有稳定作用。在这里,我们旨在通过在螺旋茎区域的疏水性核心位置引入单个半胱氨酸残基来设计 3G 抗性 CDV F 突变体。生成了共价连接的 F 二聚体,这突出了茎内的构象灵活性,以实现这些不规则的 F 构象。我们的研究结果表明,“顶部茎”CDV F 半胱氨酸突变体(F-V571C 和 F-L575C)仍然具有功能,并对 3G 产生抗性。相反,尽管并非所有“底部茎”F 半胱氨酸变体都保持适当的生物活性,但那些保持功能的变体仍对 3G 敏感。根据最近确定的预融合 MeV F 三聚体/AS-48 共晶结构,CDV 残基 F-V571 和 F-L575 可能直接与 3G 相互作用。构象特异性抗 F 抗体和低分辨率电子显微镜结构分析的组合证实,3G 对“顶部茎”F 半胱氨酸突变体失去了稳定作用,因此提示了一种主要的耐药机制。总体而言,我们的数据表明,融合抑制剂 3G 通过与茎域顶部对接来稳定预融合 CDV F 三聚体。